Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roflumilast in COPD
NCT00062582Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2003
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Roflumilast Arm with Placebo Arm (2 arms). Primary endpoint: Pulmonary function at 24 weeks. Started Jun 2003; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00062582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062582.